Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 306-312 , March 2007

A community-based study of chronic kidney disease among type 2 diabetics in Kinmen, Taiwan

  • Ching-Heng Lin

      Affiliations

    • Community Medicine Research Center, Institute of Public Health, National Yang-Ming University, Shih-Pai, 112 Taipei, Taiwan
    • ,
  • Wu-Chang Yang

      Affiliations

    • Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Shih-Tzer Tsai

      Affiliations

    • Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
    • ,
  • Tao-Hsin Tung

      Affiliations

    • Cheng Hsin Rehabilitation Medical Center, Taipei, Taiwan
    • ,
  • Pesus Chou

      Affiliations

    • Community Medicine Research Center, Institute of Public Health, National Yang-Ming University, Shih-Pai, 112 Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 28267050; fax: +886 2 28201461.

Received 25 October 2005 ,Accepted 30 June 2006.

Reference 

  1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999;341:1127–1133
  2. Held PJ, Port FK, Blagg CR, Agodoa LY. The United States Renal Data System's 1990 Annual Data Report: an introduction. Am. J. Kidney Dis. (Suppl 2). 1990;16:1–106
  3. Nelson RG, Newman JM, Knowler WC, Sievers ML, Kunzelman CL, Pettitt DJ, et al. Incidence of end-stage renal disease in type 2 diabetes mellitus in Pima Indians. Diabetologia. 1988;31:730–736
  4. Kshirsagar AV, Joy MS, Hogan SL, Falk RJ, Colindres RE. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am. J. Kidney Dis. 2000;35:695–707
  5. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001;135:73–87
  6. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004;351:1952–1961
  7. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann. Intern. Med. 1996;124:627–632
  8. Kawazu S, Tomono S, Shimizu M, Kato N, Ohno T, Ishii C, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes mellitus. The effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J. Diabetes Complications. 1994;8:13–17
  9. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995;28:103–117
  10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification: Kidney Disease Outcome Quality Initiative. Am. J. Kidney Dis. 39 (2002) S1–S266.
  11. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–3277
  12. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J. Am. Soc. Nephrol. 2003;14:S131–S138
  13. Chou P, Liao MJ, Kuo HS, Hsiao KJ, Tsai ST. A population survey on the prevalence of diabetes in Kin-Hu, Kinmen. Diabetes Care. 1994;17:1055–1058
  14. World Health Organization, Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus, World Health Organization, Geneva, 1999.
  15. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N. Engl. J. Med. 1983;309:1543–1546
  16. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24h urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316:504–509
  17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999;130:461–470
  18. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int. 2000;55:1878–1884
  19. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165–2175
  20. Ohno T, Kato N, Shimizu M, Ishii C, Ito Y, Tomono S, et al. Effect of age on the development or progression of albuminuria in non-insulin-dependent diabetes mellitus (NIDDM) without hypertension. Diabetes Res. 1993;22:115–121
  21. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 1984;311:89–93
  22. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430–1432
  23. Selby JV, FitzSimmons SC, Newman JM, Katz PP, Sepe S, Showstack J. The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control. JAMA. 1990;263:1954–1960
  24. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 2001;134:629–636
  25. Wheeler DC. Lipids—what is the evidence for their role in progressive renal disease?. Nephrol. Dial. Transplant. 1995;10:14–16
  26. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension. 1995;26:610–615
  27. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol. 2002;13:2888–2897
  28. Morales JV, Weber R, Wagner MB, Barros EJ. Is morning urinary protein/creatinine ratio a reliable estimator of 24-hour proteinuria in patients with glomerulonephritis and different levels of renal function?. J. Nephrol. 2004;17:666–672
  29. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ. 1998;317:307–312
  30. Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch. Intern. Med. 2001;161:1207–1216

PII: S0168-8227(06)00297-X

doi: 10.1016/j.diabres.2006.06.028

Diabetes Research and Clinical Practice
Volume 75, Issue 3 , Pages 306-312 , March 2007

Article Tools

* Image Usage & Resolution